Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Artios Launches With £25m To Study ‘PARP-esque’ DNA Damage Response Inhibitors

Executive Summary

Next generation DNA repair is the basis of new oncology-focused Artios Pharma, which has launched with a £25m series A round and a ‘PARP-esque’ discovery program.

Advertisement

Related Content

VC Roundup: Early-Stage Funding Slips Again In Third Quarter, Plus 15 New Financings
UK's Mission Banks £60m To Develop DUB Inhibitors

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register